NRSN — Neurosense Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $13.20m
- $12.52m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 6-K |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 1.24 | 2.89 | 5.59 | 13.6 | 12 |
Operating Profit | -1.24 | -2.89 | -5.59 | -13.6 | -12 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.22 | -2.83 | -4.04 | -12.3 | -10.1 |
Net Income After Taxes | -1.22 | -2.83 | -4.04 | -12.3 | -10.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.22 | -2.83 | -4.04 | -12.3 | -10.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.22 | -2.83 | -4.04 | -12.3 | -10.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.108 | -0.249 | -0.369 | -1.07 | -0.741 |
Dividends per Share |